AAV variant delivered genes to human immune cells at lower doses

An engineered adeno-associated virus (AAV) variant delivered genes into primary human T cells and natural killer (NK) cells at nearly 100-1,000-fold lower doses than AAV6, Hong and colleagues reported. Called AAV.APR31, it also outperformed AAV-hT7, a variant adapted to enter human T cells. It supported several forms of genetic engineering, including the production of CAR-T cells, T cells engineered with a receptor that targets cancer. Systemic administration of these cells produced potent tumor control in mouse models of blood and solid tumors.
AAV vectors carry genetic instructions into cells. They have been used for precise genome engineering in human T cells, but their poor ability to enter those cells limits their efficiency and potential use. Hong and colleagues used directed evolution to alter the protein shell of AAV6, generating variants and selecting them in primary human T cells.
The selected family carried an APR motif, a short protein sequence at positions 455-457 of the shell. Screening with CRISPR identified CD7 as an enhancer of entry specific to the cell lineage, alongside the established AAVR pathway, a route the virus uses to enter cells. Structural analysis suggested that the APR sequence helped the virus engage CD7.
AAV.APR31 supported temporary delivery of an introduced gene into human T and NK cells, as well as insertion of genetic material at a specified location in the genome. It also supported integration using a transposon, a genetic element that inserts DNA into the genome. Existing delivery systems are confined to one engineering mode, according to the researchers.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].